Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cardiff Oncology, Inc. | a14-13140_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2014
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35558 |
|
27-2004382 |
|
(State or other jurisdiction |
|
(Commission File |
|
IRS Employer |
|
of incorporation or organization) |
|
Number) |
|
Identification No.) |
11055 Flintkote Avenue, Suite B
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On May 20, 2014, Trovagene, Inc. ( the “Company”) issued a press release announcing that that data published from ongoing clinical validation studies demonstrate that the Company’s precision cancer monitoring technology is suitable to non-invasively determine oncogene mutation status in patients with malignant disease.. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information contained in Item 8.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
|
|
99.1 |
Press Release of Trovagene, Inc. dated May 20, 2014, |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 20, 2014
|
|
TROVAGENE, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Antonius Schuh |
|
|
|
Antonius Schuh |
|
|
|
Chief Executive Officer |